Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative
therapy for high-risk hematological malignancies, but the development of severe and/or …

Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid
immunosuppression. Clinical response after 1 week of therapy often guides further treatment …

Abstract Since March 2020, the COVID‐19 pandemic has led to the need to re‐think the
delivery of services to patients with chronic dysimmune neuropathies. Telephone/video …

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell
transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to …

Background Viral infections are common complications following allogeneic hematopoietic
stem cell transplantation (allo-HSCT). Allo-HSCT recipients with steroid …

Glutathione (GSH), the most abundant nonprotein thiol functioning as an antioxidant, plays
critical roles in maintaining the core functions of mesenchymal stem cells (MSCs), which are …

The intensive and prolonged immunosuppressive therapy required to prevent or treat graft-
versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts …

The standard primary treatment for acute graft-versus-host disease (GVHD) requires
prolonged, high-dose systemic corticosteroids (SCSs) that delay reconstitution of the …

This study aimed to characterize the incidence, etiology and outcome of infectious episodes
in patients with steroid refractory acute GvHD (SR-GvHD). The cohort included 127 adults …

Cytomegalovirus (CMV) infection is a major complication in allogeneic stem cell
transplantation. The utility of CMV prophylaxis with letermovir has been reported; however …